These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 29972340)

  • 1. Multifaceted activity of N-acetyl-l-cysteine in chronic obstructive pulmonary disease.
    Calzetta L; Matera MG; Rogliani P; Cazzola M
    Expert Rev Respir Med; 2018 Aug; 12(8):693-708. PubMed ID: 29972340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oxidation pathway and exacerbations in COPD: the role of NAC.
    Matera MG; Calzetta L; Cazzola M
    Expert Rev Respir Med; 2016; 10(1):89-97. PubMed ID: 26567752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine.
    Rogliani P; Matera MG; Page C; Puxeddu E; Cazzola M; Calzetta L
    Respir Res; 2019 May; 20(1):104. PubMed ID: 31133026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxidative stress and respiratory system: pharmacological and clinical reappraisal of N-acetylcysteine.
    Santus P; Corsico A; Solidoro P; Braido F; Di Marco F; Scichilone N
    COPD; 2014 Dec; 11(6):705-17. PubMed ID: 24787454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of thiols and implications for the use of inhaled corticosteroids in the presence of oxidative stress in COPD.
    Cazzola M; Page CP; Wedzicha JA; Celli BR; Anzueto A; Matera MG
    Respir Res; 2023 Jul; 24(1):194. PubMed ID: 37517999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological investigation on the anti-oxidant and anti-inflammatory activity of N-acetylcysteine in an ex vivo model of COPD exacerbation.
    Cazzola M; Calzetta L; Facciolo F; Rogliani P; Matera MG
    Respir Res; 2017 Jan; 18(1):26. PubMed ID: 28118826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. N-Acetylcysteine mucolysis in the management of chronic obstructive pulmonary disease.
    Sadowska AM
    Ther Adv Respir Dis; 2012 Jun; 6(3):127-35. PubMed ID: 22361928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The application of N-acetylcysteine in optimization of specific pharmacological therapies].
    Hołyńska-Iwan I; Wróblewski M; Olszewska-Słonina D; Tyrakowski T
    Pol Merkur Lekarski; 2017 Sep; 43(255):140-144. PubMed ID: 28987048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N-Acetylcysteine protects human bronchi by modulating the release of neurokinin A in an ex vivo model of COPD exacerbation.
    Calzetta L; Rogliani P; Facciolo F; Rinaldi B; Cazzola M; Matera MG
    Biomed Pharmacother; 2018 Jul; 103():1-8. PubMed ID: 29635121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on the pathological processes, molecular biology, and clinical utility of N-acetylcysteine in chronic obstructive pulmonary disease.
    Tse HN; Tseng CZ
    Int J Chron Obstruct Pulmon Dis; 2014; 9():825-36. PubMed ID: 25125976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antioxidant and anti-inflammatory efficacy of NAC in the treatment of COPD: discordant in vitro and in vivo dose-effects: a review.
    Sadowska AM; Manuel-Y-Keenoy B; De Backer WA
    Pulm Pharmacol Ther; 2007; 20(1):9-22. PubMed ID: 16458553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Existing and potential therapeutic uses for N-acetylcysteine: the need for conversion to intracellular glutathione for antioxidant benefits.
    Rushworth GF; Megson IL
    Pharmacol Ther; 2014 Feb; 141(2):150-9. PubMed ID: 24080471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of mucolytics in COPD: A Delphi consensus study.
    Papi A; Avdeev S; Calverley PMA; Cordeiro CR; Jesenak M; Koblížek V; Petkova D; Rogliani P; Tarraf H; Tzanakis N; Ulmeanu R; Uzaslan E; Adir Y
    Respir Med; 2020 Dec; 175():106190. PubMed ID: 33217537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of N-acetylcysteine in the management of COPD.
    Sadowska AM; Verbraecken J; Darquennes K; De Backer WA
    Int J Chron Obstruct Pulmon Dis; 2006; 1(4):425-34. PubMed ID: 18044098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New developments in the treatment of COPD: comparing the effects of inhaled corticosteroids and N-acetylcysteine.
    van Overveld FJ; Demkow U; Górecka D; de Backer WA; Zielinski J
    J Physiol Pharmacol; 2005 Sep; 56 Suppl 4():135-42. PubMed ID: 16204787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The application of n-acetylcysteine as an antioxidant and mucolytic in mechanical ventilation in intensive care patients. A prospective, randomized, placebo-controlled, double-blind study].
    Konrad F; Schoenberg MH; Wiedmann H; Kilian J; Georgieff M
    Anaesthesist; 1995 Sep; 44(9):651-8. PubMed ID: 7485927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of N-acetylcysteine and ambroxol in anti-oxidant therapy.
    Gillissen A; Nowak D
    Respir Med; 1998 Apr; 92(4):609-23. PubMed ID: 9659525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Anti-inflammatory efficacy of N-acetylcysteine and therapeutic usefulness].
    Gillissen A
    Pneumologie; 2011 Sep; 65(9):549-57. PubMed ID: 21761386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-acetylcysteine.
    Altern Med Rev; 2000 Oct; 5(5):467-71. PubMed ID: 11056417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N-Acetyl Cysteine Has Both Gastro-Protective and Anti-Inflammatory Effects in Experimental Rat Models: Its Gastro-Protective Effect Is Related to Its In Vivo and In Vitro Antioxidant Properties.
    Atalay F; Odabasoglu F; Halici M; Cadirci E; Aydin O; Halici Z; Cakir A
    J Cell Biochem; 2016 Feb; 117(2):308-19. PubMed ID: 25941092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.